B-hCLDN18.2 BxPC-3_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

Please input keywords

Order

*Country

United States

China

France

Germany

Netherlands

United Kingdom

Japan

South Korea

Israel

Australia

Hong Kong, China

New Zealand

Russia

Singapore

Taiwan, China

India

Aland Islands

Albania

Algeria

American Samoa

Andorra

Angola

Anguilla

Antarctica

Antigua & Barbuda

Argentina

Armenia

Aruba

Ascension Island

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Benin

Bermuda

Bhutan

Bolivia

Bosnia & Herzegovina

Botswana

Brazil

British Indian Ocean Territory

British Virgin Islands

Brunei

Bulgaria

Burkina Faso

Burundi

Cambodia

Cameroon

Canada

Canary Islands

Cape Verde

Caribbean Netherlands

Cayman Islands

Central African Republic

Ceuta & Melilla

Chad

Chile

Christmas Island

Cocos (Keeling) Islands

Colombia

Comoros

Congo - Brazzaville

Congo - Kinshasa

Cook Islands

Costa Rica

Côte d’Ivoire

Croatia

Cuba

Curaçao

Cyprus

Czechia

Denmark

Diego Garcia

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Ethiopia

Falkland Islands

Faroe Islands

Fiji

Finland

French Guiana

French Polynesia

French Southern Territories

Gabon

Gambia

Georgia

Ghana

Gibraltar

Greece

Greenland

Grenada

Guadeloupe

Guam

Guatemala

Guernsey

Guinea

Guinea-Bissau

Guyana

Haiti

Honduras

Hungary

Iceland

Indonesia

Iran

Iraq

Ireland

Isle of Man

Italy

Jamaica

Jersey

Jordan

Kazakhstan

Kenya

Kiribati

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Macau, China

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Martinique

Mauritania

Mauritius

Mayotte

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Montserrat

Morocco

Mozambique

Myanmar (Burma)

Namibia

Nauru

Nepal

New Caledonia

Nicaragua

Niger

Nigeria

Niue

Norfolk Island

North Korea

Northern Mariana Islands

Norway

Oman

Pakistan

Palau

Palestinian Territories

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Pitcairn Islands

Poland

Portugal

Puerto Rico

Qatar

Réunion

Romania

Rwanda

Samoa

San Marino

São Tomé & Príncipe

Saudi Arabia

Senegal

Serbia

Seychelles

Sierra Leone

Sint Maarten

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Georgia & South Sandwich Islands

South Sudan

Spain

Sri Lanka

St. Barthélemy

St. Helena

St. Kitts & Nevis

St. Lucia

St. Martin

St. Pierre & Miquelon

St. Vincent & Grenadines

Sudan

Suriname

Svalbard & Jan Mayen

Swaziland

Sweden

Switzerland

Syria

Tajikistan

Tanzania

Thailand

Timor-Leste

Togo

Tokelau

Tonga

Trinidad & Tobago

Tristan da Cunha

Tunisia

Turkey

Turkmenistan

Turks & Caicos Islands

Tuvalu

U.S. Outlying Islands

U.S. Virgin Islands

Uganda

Ukraine

United Arab Emirates

United Nations

Uruguay

Uzbekistan

Vanuatu

Vatican City

Venezuela

Vietnam

Wallis & Futuna

Western Sahara

Yemen

Zambia

Zimbabwe

*Province

*City

*Name

*Telephone

*Company

*Position

*Email

*Verification code

*Verification Code

Home

Animal models

Animal / cell resources

Humanized Tumor Cell Lines

Humanized Cell Lines

Text

B-hCLDN18.2 BxPC-3

Common name	B-hCLDN18.2 BxPC-3	Catalog number	321827
Aliases	/	Disease	Pancreatic adenocarcinoma
Organism	Human	Strain	Human
Tissue types	Pancreas	Tissue	Pancreas

Description

The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly. Human CLDN18.2 is highly expressed on the surface of B-hCLDN18.2 BxPC-3 cells.

Application

B-hCLDN18.2 BxPC-3 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hCLDN18.2 BxPC-3 cells. The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly.

Protein expression analysis

CLDN18.2 expression analysis in B-hCLDN18.2 BxPC-3 cells by flow cytometry. Single cell suspensions from B-hCLDN18.2 BxPC-3 cultures were stained with species-specific anti-CLDN18.2 antibody. Human CLDN18.2 was detected on the surface of B-hCLDN18.2 BxPC-3 cells. The 1-A04 clone of B-hCLDN18.2 BxPC-3 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

from clipboard

Subcutaneous homograft tumor growth of B-hCLDN18.2 BxPC-3 cells. B-hCLDN18.2 BxPC-3 cells (1x10⁷) and wild-type BxPC-3 cells (1x10⁷) were subcutaneously implanted into B-NDG mice (female, 9-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hCLDN18.2 BxPC-3 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hCLDN18.2 BxPC-3 cells were subcutaneously transplanted into B-NDG mice (n=5), and on 77 days post inoculation, tumor cells were harvested and assessed for human CLDN18.2 expression by flow cytometry. As shown, human CLDN18.2 was highly expressed on the surface of tumor cells. Therefore, B-hCLDN18.2 BxPC-3 cells can be used for in vivo efficacy studies of novel CLDN18.2 therapeutics.